MYC protein expression is an important prognostic factor in acute myeloid leukemia
暂无分享,去创建一个
Z. Estrov | M. Andreeff | K. Bhalla | Jianhua Zhang | H. Kantarjian | G. Garcia-Manero | A. Futreal | J. Cortes | S. Verstovsek | Xuelin Huang | T. Kadia | F. Ravandi | Koichi Takahashi | G. Borthakur | S. Pierce | R. Kanagal-Shamanna | S. Kornblau | S. Post | L. Medeiros | C. Bueso-Ramos | L. Abruzzo | S. Loghavi | Z. Zuo | G. Nogueras-Gonzalez | M. Ohanian | Y. Huh | U. Rozovski | J. Cortes | P. Ruvolo | Peter Hu | M. Hornbaker | C. Bueso‐Ramos
[1] J. Sierra,et al. CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome . , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] J. Sierra,et al. CD34+ selection vs. reduced-intensity conditioning and unmodified graft for allogeneic hematopoietic cell transplantation in patients with AML and MDS > 50 years , 2018 .
[3] M. Dawson,et al. A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML) , 2017 .
[4] J. Foran,et al. Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions. , 2017, The Ochsner journal.
[5] J. Nilsson,et al. Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers , 2017, British journal of haematology.
[6] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[7] A. Mansoor,et al. Acute myeloid leukaemia: expression of MYC protein and its association with cytogenetic risk profile and overall survival , 2017, Hematological oncology.
[8] G. He,et al. 2016 Revision to the WHO classification of acute myeloid leukemia , 2017, Journal of translational internal medicine.
[9] M. Konopleva,et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia , 2017, Cancer.
[10] C. Bueso-Ramos,et al. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype. , 2016, Cancer genetics.
[11] Z. Estrov,et al. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. , 2015, Cancer genetics.
[12] C. Craddock,et al. In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available? , 2015, Bone Marrow Transplantation.
[13] M. McArthur,et al. hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. , 2015, Cancer cell.
[14] H. Kantarjian,et al. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis , 2015, British journal of haematology.
[15] J. León,et al. MYC as therapeutic target in leukemia and lymphoma , 2015 .
[16] R. Stone. Should older adults with AML receive post-remission therapy? , 2015, Best practice & research. Clinical haematology.
[17] E. Estey,et al. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Sheng Wei,et al. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. , 2015, Leukemia research.
[19] Yu Cao,et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.
[20] D. Dill,et al. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. , 2014, Cancer cell.
[21] K. Patel,et al. Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization , 2014, Leukemia & lymphoma.
[22] S. Robson,et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia , 2013, Leukemia.
[23] R. Fanin,et al. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients , 2013, American journal of hematology.
[24] T. Naoe,et al. The demarcation between younger and older acute myeloid leukemia patients: A pooled analysis of 3 prospective studies , 2013, Cancer.
[25] C. Bloomfield,et al. New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461 , 2013, Genes, chromosomes & cancer.
[26] J. León,et al. MYC oncogene in myeloid neoplasias , 2013, Clinical and Translational Oncology.
[27] D. Weisdorf,et al. Survival for older patients with acute myeloid leukemia: a population-based study , 2012, Haematologica.
[28] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. Konopleva,et al. Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients , 2012, Cancer.
[30] Chi V Dang,et al. MYC on the Path to Cancer , 2012, Cell.
[31] B. Lüscher,et al. Regulation of gene transcription by the oncoprotein MYC. , 2012, Gene.
[32] H. Erba. Has there been progress in the treatment of older patients with acute myeloid leukemia? , 2010, Best practice & research. Clinical haematology.
[33] J. Dick,et al. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. , 2009, Blood.
[34] R. Eisenman,et al. Myc's broad reach. , 2008, Genes & development.
[35] Kyu-Tae Kim,et al. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells , 2007, British journal of haematology.
[36] N. Young,et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. , 2006, Blood.
[37] A. W. Harris,et al. MYC levels govern hematopoietic tumor type and latency in transgenic mice. , 2006, Blood.
[38] Gerhard Ehninger,et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.
[39] H. Gundacker,et al. Age and acute myeloid leukemia. , 2006, Blood.
[40] E. Estey. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. , 2006, Seminars in hematology.
[41] W. Hiddemann,et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.
[42] Stefan Fröhling,et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.
[43] D. Gilliland,et al. Drug therapy for acute myeloid leukemia. , 2005, Blood.
[44] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[45] D. Rimm,et al. X-Tile , 2004, Clinical Cancer Research.
[46] M. Wigler,et al. Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.
[47] Ping Ji,et al. Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells , 2004, Molecular and Cellular Biology.
[48] A. Sánchez-Aguilera,et al. Cell cycle deregulation in B-cell lymphomas. , 2003, Blood.
[49] M. Keating,et al. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. , 2001, American journal of clinical pathology.
[50] R. Clark,et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.
[51] W. Hiddemann,et al. Management of acute myeloid leukemia in elderly patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] E. Prochownik,et al. Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation , 1986, Nature.
[53] E. Dmitrovsky,et al. Expression of a transfected human c-myconcogene inhibits differentiation of a mouse erythroleukaemia cell line , 1986, Nature.
[54] M. Cole,et al. Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment , 1986, Nature.
[55] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .
[56] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .